Ketorolac IV Push Dosing and Administration
For adults without renal impairment, advanced age (≥65 years), or low body weight (<50 kg), administer ketorolac 30 mg IV push over no less than 15 seconds as a single dose, or 30 mg every 6 hours (maximum 120 mg/day) for multiple-dose treatment, not to exceed 5 days total duration. 1
Standard Dosing Protocol
Single-Dose Administration
- Standard adult dose: 30 mg IV push over ≥15 seconds 1
- Onset: Analgesic effect begins in approximately 30 minutes, with maximum effect at 1-2 hours 1
- Duration: 4-6 hours of pain relief 1
Multiple-Dose Regimen
- Dose: 30 mg IV every 6 hours 1
- Maximum daily dose: 120 mg 1
- Maximum duration: 5 days total (including any oral ketorolac) 1
Administration Technique
The IV bolus must be given over no less than 15 seconds 1. This is critical—rapid administration should be avoided. Do not mix ketorolac in a syringe with morphine sulfate, meperidine hydrochloride, promethazine hydrochloride, or hydroxyzine hydrochloride, as this will cause precipitation 1.
Dose-Response Evidence
Recent high-quality evidence demonstrates that lower doses may provide equivalent analgesia. A 2017 randomized controlled trial comparing 10 mg, 15 mg, and 30 mg IV ketorolac found no significant differences in pain reduction at 30 minutes, with all three doses providing substantial relief (mean pain score reduction from ~7.7 to ~5.0 on a 0-10 scale) 2. A 2023 systematic review confirmed that 15-20 mg doses probably have no difference in pain scores compared to ≥30 mg doses (mean difference 0.05 mm on 100 mm VAS, 95% CI -4.91 to +5.01 mm) 3.
However, for standard practice in adults without risk factors, the FDA-approved 30 mg dose remains the recommended starting point 1, as lower doses may increase the need for rescue analgesia 3.
Special Populations Requiring Dose Reduction
Elderly (≥65 years)
Low Body Weight (<50 kg/110 lbs)
Renal Impairment
- Moderately elevated creatinine: 15 mg IV every 6 hours (maximum 60 mg/day) 1
- Advanced renal impairment: Contraindicated 1
Critical Safety Considerations
Absolute Contraindications
- Active peptic ulcer disease or GI bleeding 1
- Advanced renal impairment 1
- Suspected/confirmed cerebrovascular bleeding 1
- Hemorrhagic diathesis or high bleeding risk 1
- CABG surgery setting 1
- Concurrent NSAID or aspirin use 1
- Pregnancy/labor 1
- Prior hypersensitivity to ketorolac or NSAIDs 1
Duration Limits
Never exceed 5 days of total ketorolac use (IV plus oral combined) 1. Increasing the dose beyond label recommendations will not improve efficacy but will increase serious adverse event risk 1.
Monitoring
Elderly patients are at greater risk for serious GI events 1. The drug inhibits platelet function, so avoid in patients at high bleeding risk 1. Correct hypovolemia before administration to reduce renal risk 1.
Clinical Context
Ketorolac provides opioid-level analgesia for moderate to severe acute pain, typically in postoperative settings 1. Guidelines support its use for acute pain management, with cancer pain guidelines recommending 15-30 mg IV for short-term use (maximum 5 days) 4. For migraine, older guidelines listed 60 mg IM every 15-30 minutes (maximum 120 mg/day) 5, though IV dosing follows the same principles.
For breakthrough pain, do not increase the dose or frequency—instead, consider supplementing with low-dose opioids if not contraindicated 1.